美股市场个股详情
REPL Replimune
- 6.560
- +0.080+1.23%
收盘价 05/02 16:00 (美东)
4.03亿总市值-2075市盈率TTM
6.660最高价6.370最低价72.33万股成交量6.540今开6.480昨收473.99万成交额1.85%换手率亏损市盈率(静)6138.78万总股本24.81052周最高0.96市净率2.56亿流通值5.86052周最低--股息TTM3904.99万流通股54.850历史最高--股息率TTM4.48%振幅5.860历史最低6.553平均价1股每手
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
Replimune股票讨论区
NEWS
Replimune Group, Inc. announced positive interim results from the ARTACUS Phase 1/2 clinical trial evaluating RP1 monotherapy for skin cancers in transplant patients, showing a 34.8% overall response rate with good durability. The treatment was well-tolerated and resulted in immune activation.
The reason why I am interested in oncolytic virus is that the virus itself is a kind of drug, and at the same time, the virus can become the carrier of other drugs. This dual property is not possessed by other drugs at present, and it is up to us to fully exploit this function.$Replimune(REPL.US)$$Candel Therapeutics(CADL.US)$
暂无评论